(August 24, 2016, 12:59 PM EDT) -- ALEXANDRIA, Va. — Assertions that an Aventis Pharma S.A. patent is invalid as obvious under 35 U.S. Code Section 103 were rejected Aug. 23 by the Patent Trial and Appeal Board,...
Patent Board Denies Mylan Bid For Review Of Taxoid Patent
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login